Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785975 | Cancer Treatment Reviews | 2016 | 7 Pages |
Abstract
Combination of targeted agents and endocrine therapy results in concordant, superior PFS suggesting targetable endocrine resistance across metastatic sites. Discordant responses with endocrine strategy alone support use of targeted therapy, rather than change in endocrine agent at disease progression. HER2 targeted therapies may be less effective in areas of poor vascularization.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Saroj Niraula, Alberto Ocana,